Ensuring The Next Generation Of Health Care Professionals: Still An Unmet Need

Health Care Is At A ‘Crucial Point’ On Its Journey To The Future Says Philips

 
• By Ashley Yeo
  
Generate a summary of this article
Listen to this article
Beta

For its fifth annual Future Health Index, Royal Philips chose to focus on the insights and needs of health care professionals below the age of 40, a group that often feels unheard, and yet will form the basis of the workforce over the next two decades. Getting it right from their point of view is vital.

Business_People_Shadows

“The findings of the Future Health Index (FHI) 2020 demonstrate that we are at a crucial moment in the journey to the future of health care.” So said Jan Kimpen, chief medical officer at Royal Philips NV, as the group published the fifth annual edition in its series of FHI reports. The survey, of some 3,000 young doctors and nurses from 15 countries, reveals that unmet needs can apply to health care providers and health care professionals (HCPs), as well as patients.

The goal of the Philips Future Health indexes is to understand customers better and cater to their needs, especially in...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from Business Strategy

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

test carousel

 
• By Saba Afreen

test carousel-In-Vivo

Slow Progress: A Decade Of Cell Therapy In Japan

 
• By Lisa Takagi

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.

More from In Vivo

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

In Vivo’s 2026 Rising Leaders-Part 1

 
• By Saba Afreen

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

XXXXtesting

 
• By Saba Afreen

XXXXtesting